Effects of striatal ΔFosB over expression and ketamine on social defeat stress-induced anhedonia in mice

Biological Psychiatry

Volumn 76, Issue 7, 2014, Pages 550-558

  Donahue, Rachel J ^a   Muschamp, John W ^a   Russo, Scott J ^a   Nestler, Eric J ^b   Carlezon, William A ^b  

^a MCLEAN HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anhedonia; Antidepressant; Defeat; Intracranial selfstimulation (ICSS); Ketamine; Social interaction; Stress

Indexed keywords

KETAMINE; TRANSCRIPTION FACTOR FOSB; ANTIDEPRESSANT AGENT; FOSB PROTEIN, MOUSE; PROTEIN C FOS;

ACUTE DRUG ADMINISTRATION; ANHEDONIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COPING BEHAVIOR; CORPUS STRIATUM; DEPRESSION; DRUG EFFECT; DRUG MEGADOSE; HYPOTHALAMUS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REWARD; SOCIAL AVOIDANCE BEHAVIOR; SOCIAL INTERACTION; SOCIAL STRESS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ELECTROSTIMULATION; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SELF STIMULATION; SOCIAL BEHAVIOR;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; CORPUS STRIATUM; ELECTRIC STIMULATION; HYPOTHALAMUS; KETAMINE; MALE; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-FOS; REWARD; SELF STIMULATION; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 84914698140     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.12.014     Document Type: Article

References (92)

1. Finlay-Jones R, Brown GW (1981): Types of stressful life event and the onset of anxiety and depressive disorders. Psychol Med 11: 803-815.
2. Keller MC, Neale MC, Kendler KS (2007): Association of different adverse life events with distinct patterns of depressive symptoms. Am J Psychiatry 164:1521-1529.
3. Kendler KS, Karkowski LM, Prescott CA (1999): Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 156:837-848.
4. Kessler RC, Berglund P, Demler O, Jim R, Merikangas KR, Walters EE (2005): Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
5. Keller MB, Boland RJ (1998): Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 44:348-360.
6. Nemeroff CB (2007): Prevalence and management of treatmentresistant depression. J Clin Psychiatry 68:17-25.
7. Krishnan V, Nestler EJ (2008): The molecular neurobiology of depression. Nature 455:894-902.
8. American Psychiatric Association (2000): Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association.
9. Nestler EJ, Hyman SE (2010): Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161-1169.
10. Golden SA, Covington HE III, Berton O, Russo SJ (2011): A standardized protocol for repeated social defeat stress in mice. Nat Protoc 6: 1183-1191.
11. Huhman KL (2006): Social conflict models: Can they inform us about human psychopathology? Horm Behav 50:640-646.
12. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. (2006): Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311:864-868.
13. Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, et al. (2007): Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131:391-404.
14. Kudryavtseva NN, Bakshtanovskaya IV, Koryakina LA (1991): Social model of depression in mice of C57BL/6J strain. Pharmacol Biochem Behav 38:315-320.
15. Cao JL, Covington HE III, Friedman AK, Wilkinson MB, Walsh JJ, Cooper DC, et al. (2010): Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J Neurosci 30:16453-16458.
16. Covington HE III, Maze I, LaPlant QC, Vialou VF, Yoshinori ON, Berton O, et al. (2009): Antidepressant actions of histone deacetylase inhibitors. J Neurosci 29:11451-11461.
17. Chaouloff F (2013): Social stress models in depression research: What do they tell us? Cell Tissue Res 354:179-190.
18. Kalueff AV, Avgustinovich DF, Kudryavtseva NN, Murphy DL (2006): BDNF in anxiety and depression. Science 312:1598-1599.
19. Carlezon WA Jr, Chartoff EH (2007): Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995.
20. Der-Avakian A, Markou A (2012): The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 35:68-77.
21. Barr AM, Markou A, Phillips AG (2003): A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 23:475-482.
22. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998): Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76-79.
23. Johnson PM, Hollander JA, Kenny PJ (2008): Decreased brain reward function during nicotine withdrawal in C57BL6 mice: Evidence from intracranial self-stimulation (ICSS) studies. Pharmacol Biochem Behav 90:409-415.
24. Liu J, Schulteis G (2004): Brain reward deficits accompany naloxoneprecipitated withdrawal from acute opioid dependence. Pharmacol Biochem Behav 79:101-108.
25. Markou A, Hauger RL, Koob GF (1992): Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology (Berl) 109: 305-314.
26. Lin D, Bruijnzeel AW, Schmidt P, Markou A (2002): Exposure to chronic mild stress alters thresholds for lateral hypothalamic stimulation reward and subsequent responsiveness to amphetamine. Neuroscience 114:925-933.
27. Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE (1992): Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum selfstimulation behavior in rats. Eur J Neuropsychopharmacol 2:43-49.
28. Di Nieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, et al. (2006): Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci 29: 1855-1859.
29. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr (2004): Effects of kappa-opioid ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 172:463-470.
30. Martin D, Lodge D (1985): Ketamine acts as a non-competitive Nmethyl- D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology 24:999-1003.
31. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. (2000): Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
32. Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, et al. (2013): Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: A preliminary positron emission tomography study. Biol Psychiatry 73: 1213-1221.
33. Correll GE, Futter GE (2006): Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 7:92-95.
34. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. (2010): A randomized add-on trial of an N-methyl-Daspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802.
35. Larkin GL, Beautrais (2011): A preliminary naturalistic study of lowdose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14:1127-1131.
36. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr (2009): Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65:181-184.
37. Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, et al. (2010): Anterior cingulated desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415-1422.
38. Price RB, Nock MK, Charney DS, Mathew SJ (2009): Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522-526.
39. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. (2006): A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
40. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. (2011): NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 475:91-95.
41. Bechtholt-Gompf AJ, Smith KL, John CS, Kang HH, Carlezon WA Jr, Cohen BM, et al. (2011): CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology 215:689-695.
42. Da Silva FC, do Carmo de Oliveira Cito M, da Silva MI, Moura BA, de Aquino Neto MR, Feitosa ML, et al. (2010): Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. Brain Res Bull 83:9-15.
43. Engin E, Treit D, Dickson CT (2009): Anxiolytic- And antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 161:359-369.
44. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. (2008): Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32:140-144.
45. Koike H, Iijima M, Chaki S (2011): Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111.
46. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. (2011): Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754-761.
47. Li N, Lee B, Lui RJ, Banasr M, Dwyer JM, Iwata M, et al. (2010): mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
48. Lindholm JSO, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC, et al. (2012): The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiators LY 451646 are preserved in bdnf (+/-) heterozygous null mice. Neuropharmacology 62: 391-397.
49. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, et al. (2013): Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase- 3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8:e56053.
50. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. (2008): Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352.
51. Popik P, Kos T, Sowa-Kucma M, Nowak G (2008): Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 198:421-430.
52. Boultadakis A, Pitsikas N (2011): Anesthetic ketamine impairs rats' recall of previous information: The nitric oxide synthase inhibitor Nnitro- L-arginine methylester antagonizes this ketamine-induced recognition memory deficit. Anesthesiology 114:1345-1353.
53. Wang JH, Fu Y, Wilson FAW, Ma YY (2006): Ketamine affects memory consolidation: Differential effects in T-maze and passive avoidance paradigms in mice. Neuroscience 140:993-1002.
54. Vialou V, Robison AJ, LaPlant QC, Covington HE, Dietz DM, Ohnishi YN, et al. (2010): ΔFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci 13:745-752.
55. Kelz MB, Chen J, Carlezon WA Jr, Whisler K, Gilden L, Beckmann AM, et al. (1999): Expression of the transcription factor ΔFosB in the brain controls sensitivity to cocaine. Nature 401:272-276.
56. Miliaressis E, Rompre PP, Labiolette P, Philippe L, Coulombe D (1986): The curve-shift paradigm in self-stimulation methodology. Physiol Behav 37:85-91.
57. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, et al. (2011): Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71:498-511.
58. Muschamp JW, Nemeth CL, Robison AJ, Nestler EJ, Carlezon WA Jr (2012): ΔFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry 71:44-50.
59. Der-Avakian A, Markou A (2010): Neonatal maternal separation exacerbates the reward-enhancing effect of acute amphetamine administration and the anhedonic effect of repeated social defeat in adult rats. Neuroscience 170:1189-1198.
60. Kureta Y, Watanabe S (1996): Influence of social dominance on selfstimulation behavior in male golden hamsters. Physiol Behav 59: 621-624.
61. Dubreucq S, Kambire S, Conforzi M, Metna-Laurent M, Cannich A, Soria-Gomez E, et al. (2012): Cannabinoid type 1 receptors located on single-minded 1-expressing neurons control emotional behaviours. Neuroscience 204:230-244.
62. Dubreucq S, Matias I, Cardinal P, Häring M, Lutz B, Marsicano G, et al. (2012): Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37:1885-1900.
63. Croft AP, Brooks SP, Cole J, Little HJ (2005): Social defeat increases alcohol preference of C57BL/10 strain mice; effect prevented by a CCKB antagonist. Psychopharmacology 183:163-170.
64. Hollis F, Wang H, Dietz D, Gunjan A, Kabbaj M (2010): The effects of repeated social defeat on long-term depressive-like behaviour and short-term histone modifications in the hippocampus in male Sprague-Dawley rats. Psychopharmacology 211:69-77.
65. Moreau JL (1997): Reliable monitoring of hedonic deficits in the chronic mild stress model of depression. Psychopharmacology 134: 357-358.
66. Willner P (2005): Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-110.
67. Bondar NP, Kovalenko IL, Avgustinovich DF, Smagin DA, Kudryavtseva NN (2009): Anhedonia in the shadow of chronic social defeat stress, or when the experimental context matters. Open Behav Sci J 3:17-27.
68. File SE (2013): Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res 125:151-157.
69. Berlin I, Givry-Steiner L, Lecrubier Y, Puech AJ (1998): Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. Eur Psychiatry 13:303-309.
70. Dichter GS, Smoski MJ, Kampov-Polevoy AB, Gallop R, Garbutt JC (2010): Unipolar depression does not moderate responses to the Sweet Taste Test. Depress Anxiety 27:859-863.
71. Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, Houshyar H, et al. (2003): Chronic stress and obesity: A new view of comfort food. Proc Natl Acad Sci U S A 100:11696-11701.
72. Dallman MF, Pecoraro NC, La Fleur SE (2005): Chronic stress and comfort foods: Self-medication and abdominal obesity. Brain Behav Immun 19:275-280.
73. Heiskanena TH, Koivumaa-Honkanena HT, Niskanenb LK, Lehtoa SM, Honkalampie KM (2013): Depression and major weight gain: A 6-year prospective follow-up of outpatients. Compr Psychiatry 54:599-604.
74. Wallace DL, Han MH, Graham DL, Green TA, Vialou V, Iñiguez SD, et al. (2009): CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nat Neurosci 12:200-209.
75. McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C (2005): Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31: 1241-1248.
76. Van't Veer A, Carlezon WA Jr (2013): Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology 229:435-452.
77. Pereira Do Carmo G, Stevenson GW, Carlezon WA Jr, Negus SS (2009): Effects of pain- And analgesia-related manipulations on intracranial self-stimulation in rats: Further studies on pain-depressed behavior. Pain 144:170-177.
78. Butler RK, Finn DP (2009): Stress-induced analgesia. Prog Neurobiol 88: 184-202.
79. Warren BL, Vialou VF, Iñiguez SD, Alcantara LF, Wright KN, Feng J, et al. (2013): Neurobiological sequelae of witnessing stressful events in adult mice. Biol Psychiatry 73:7-14.
80. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. (2012): Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37:1526-1533.
81. Parise EM, Alcantara LF, Warren BL, Wright KN, Hadad R, Sial OK, et al. (2013): Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry 74:750-759.
82. Yilmaz A, Schulz D, Aksoy A, Canbeyli R (2002): Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71:341-344.
83. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Andreazza AC, Stertz L, et al. (2008): Chronic administration of ketamine elicits antidepressantlike effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 103:502-506.
84. Aan-het-Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. (2010): Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139-145.
85. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan-het-Rot M, et al. (2012): Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250-256.
86. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, et al. (2013): Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27:444-450.
87. de la Peña IJ, Lee HL, de la Peña I, Shin CY, Sohn AR, et al. (2013): Preexposure to related substances induced place preference and selfadministration of the NMDA receptor antagonist-benzodiazepine combination, zoletil. Behav Pharmacol 24:20-28.
88. Herberg LJ, Rose IC (1989): The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward. Psychopharmacology 99:87-90.
89. Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran HV (2004): Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: A dose-response study. Psychopharmacology 172: 298-308.
90. Hancock PJ, Stamford JA (1999): Stereospecific effects of ketamine on dopamine efflux and uptake in the rat nucleus accumbens. Br J Anaesth 82:603-608.
91. Wise RA (2008): Dopamine and reward: The anhedonia hypothesis 30 years on. Neurotox Res 14:169-183.
92. Morris SE, Cuthbert BN (2012): Research domain criteria: Cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci 14:29-37.